Treatment options for bipolar depression

Journal of Clinical Psychiatry

Volumn 66, Issue 1, 2005, Pages 3-6

  Bowden, Charles L ^a  

^a Mays Cancer Center at UT Health San Antonio   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; CARBAMAZEPINE; FLUOXETINE; FLUOXETINE PLUS OLANZAPINE; IMIPRAMINE; LAMOTRIGINE; LITHIUM; LITHIUM CARBONATE; MONOAMINE OXIDASE INHIBITOR; OLANZAPINE; PAROXETINE; PLACEBO; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT; TRIMIPRAMINE; VALPROATE SEMISODIUM; VENLAFAXINE; ANTICONVULSIVE AGENT; BENZODIAZEPINE DERIVATIVE; NEUROLEPTIC AGENT; TRIAZINE DERIVATIVE;

BIPOLAR DEPRESSION; CLINICAL FEATURE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DIAGNOSTIC ERROR; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; DRUG APPROVAL; DRUG EFFICACY; FOLLOW UP; HAMILTON SCALE; HUMAN; MAJOR DEPRESSION; MONOTHERAPY; OBESITY; OUTCOME ASSESSMENT; PATIENT CARE; PRIORITY JOURNAL; PSYCHOEDUCATION; RELAPSE; REVIEW; RISK ASSESSMENT; RISK FACTOR; SYMPTOM; TREATMENT DURATION; TREATMENT INDICATION; TREATMENT OUTCOME; TREATMENT RESPONSE; BIPOLAR DISORDER; DEPRESSION; DRUG COMBINATION; GROUP THERAPY; METHODOLOGY; PATIENT EDUCATION; PSYCHOTHERAPY; RECURRENT DISEASE; SURVIVAL;

ANTICONVULSANTS; ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BIPOLAR DISORDER; DEPRESSIVE DISORDER; DRUG THERAPY, COMBINATION; FLUOXETINE; HUMANS; PATIENT EDUCATION; PSYCHOTHERAPY; PSYCHOTHERAPY, GROUP; RECURRENCE; SURVIVAL ANALYSIS; TRIAZINES;

EID: 14544288719     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (23)

1. Judd LL, Akiskal HS, Schettler PJ, et al. The long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch Gen Psychiatry 2002;59:530-537
2. Judd LL, Akiskal HS, Schettler PJ, et al. A prospective investigation of the natural history of the long-term weekly symptomatic status of bipolar II disorder. Arch Gen Psychiatry 2003;60:261-269
3. Post RM, Leverich GS, Altshuler LL, et al. An overview of recent findings of the Stanley Foundation Bipolar Network (Part I). Bipolar Disord 2003;5:310-319
4. Hantouche EG, Akiskal HS, Lancrenon S, et al. Systematic clinical methodology for validating bipolar-II disorder: data in mid-stream from a French multi-site study (EPIDEP). J Affect Disord 1998;50:163-173
5. Fagiolini A, Kupfer DJ, Houck PR, et al. Obesity as a correlate of outcome in patients with bipolar I disorder. Am J Psychiatry 2003;160:112-117
6. Bowden CL, Calabrese JR, McElroy SL, et al. A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Arch Gen Psychiatry 2000;57:481-489
7. Kalin NH. Management of the depressive component of bipolar disorder. Depress Anxiety 1996/1997;4:190-198
8. Goodwin FK, Fireman B, Simon GE, et al. Suicide risk in bipolar disorder during treatment with lithium and divalproex. JAMA 2003;290:1467-1473
9. Gyulai L, Bowden CL, McElroy SL, et al. Maintenance efficacy of divalproex in the prevention of bipolar depression. Neuropsychopharmacology 2003;28:1374-1382
10. Nemeroff CB, Evans DL, Gyulai L, et al. Double-blind, placebo-controlled comparison of imipramine and paroxetine in the treatment of bipolar depression. Am J Psychiatry 2001;158:906-912
11. Peet M. Induction of mania with selective serotonin re-uptake inhibitors and tricyclic antidepressants. Br J Psychiatry 1994;164:549-550
12. Himmelhoch JM, Thase ME, Mallinger AG, et al. Tranylcypromine versus imipramine in anergic bipolar depression. Am J Psychiatry 1991;148:910-916
13. Goodwin FK, Jamison KR. Manic-Depressive Illness. New York, NY: Oxford University Press; 1990
14. Lewis JL, Winokur G. The induction of mania: a natural history study with controls. Arch Gen Psychiatry 1982;39:303-306
15. Calabrese JR, Bowden CL, Sachs GS, et al, for the Lamictal 602 Study Group. A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. J Clin Psychiatry 1999;60:79-88
16. Vieta E, Martinez-Arán A, Goikolea JM, et al. A randomized trial comparing paroxetine and venlafaxine in the treatment of bipolar depressed patients taking mood stabilizers. J Clin Psychiatry 2002;63:508-512
17. Altshuler L, Suppes T, Black D, et al. Impact of antidepressant discontinuation after acute bipolar depression remission on rates of depressive relapse at 1-year follow-up. Am J Psychiatry 2003;160:1252-1262
18. Tohen M, Vieta E, Calabrese J, et al. Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Arch Gen Psychiatry 2003;60:1079-1088
19. Lamictal (lamotrigine). Physicians' Desk Reference. Montvale, NJ: Thomson PDR; 2004:1537-1549
20. Bowden CL, Calabrese JR, Sachs G, et al, for the Lamictal 606 Study Group. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. Arch Gen Psychiatry 2003;60:392-400
21. Calabrese JR, Bowden CL, Sachs G, et al, for the Lamictal 605 Study Group. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder. J Clin Psychiatry 2003;64:1013-1024
22. Colom F, Vieta E, Martinez-Arán A, et al. A randomized trial on the efficacy of group psychoeducation in the prophylaxis of recurrences in bipolar disorder whose disease is in remission. Arch Gen Psychiatry 2003;60:402-407
23. Vieta E. Improving treatment adherence in bipolar disorder through psychoeducation. J Clin Psychiatry 2005;66(suppl 1):24-29